Download PDF
Dtsch Med Wochenschr 2013; 138(37): 1835-1838
DOI: 10.1055/s-0033-1349428
Übersicht | Review article
Rheumatologie
© Georg Thieme Verlag KG Stuttgart · New York

Chronische Entzündung und AA-Amyloidose

Chronic inflammation and AA amyloidosis
N. Blank
1   Universitätsklinikum Heidelberg, Medizinische Klinik 5, Sektion Rheumatologie und Amyloidosezentrum, Heidelberg
,
S. O. Schönland
1   Universitätsklinikum Heidelberg, Medizinische Klinik 5, Sektion Rheumatologie und Amyloidosezentrum, Heidelberg
› Author Affiliations
Further Information

Publication History

23 April 2013

02 July 2013

Publication Date:
04 September 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die AA-Amyloidose ist eine schwerwiegende Folgeerkrankung bei chronischen entzündlichen Erkrankungen. Die Nierenbeteiligung steht im Vordergrund. Bei Patienten mit Risikofaktoren sollten regelmäßige Untersuchungen auf eine Mikroalbuminurie durchgeführt werden. Zur Therapie ist eine effektive Kontrolle der humoralen Entzündungsreaktion notwendig. Blutdruckeinstellung und andere nephroprotektive Maßnahmen tragen zum Erhalt der Nierenfunktion bei. Bei Progression der Amyloidose ist eine Nierenersatztherapie erforderlich; eine Nierentransplantation kann bei guter Kontrolle der Grunderkrankung durchgeführt werden.

Abstract

Systemic AA amyloidosis is a severe complication of chronic inflammatory diseases. Renal involvement is the predominant organ manifestation. Patients who are at risk for developing AA amyloidosis should be screened for microalbuminuria. The goal of therapy is an effective control of the acute phase reaction. A well controlled blood pressure and nephroprotective treatment contribute to the maintenance of renal function. In case of progressive amyloidosis dialysis is required. Renal transplantation can be performed if the underlying disease is well controlled.

Schlüsselwörter

rheumatoide Arthritis - Vaskulitis - autoinflammatorische Syndrome - C-reaktives Protein - Serum-Amyloid-A - Proteinurie - nephrotisches Syndrom

Keywords

rheumatoid arthritis - vasculitis - autoinflammatory syndromes - C-reactive protein - serum amyloid A - proteinuria - nephrotic syndrome
 

  • Literatur

  • 1 Aganna E, Hawkins PN, Ozen S et al. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun 2004; 5: 289-293
    CrossrefPubMedGoogle Scholar
  • 2 Akpolat T, Özkaya O, Özen S. Homozygous M694V as a risk factor for amyloidosis in Turkish FMF patients. Gene 2012; 492: 285-289
    CrossrefPubMedGoogle Scholar
  • 3 Bellotti V, Chiti F. Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases. Curr Opin Struct Biol 2008; 18: 771-779
    CrossrefPubMedGoogle Scholar
  • 4 Bergesio F, Ciciani AM, Manganaro M et al. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant 2008; 23: 941-951
    PubMedGoogle Scholar
  • 5 Bodin K, Ellmerich S, Kahan MC et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010; 468: 93-97
    CrossrefPubMedGoogle Scholar
  • 6 Booth DR, Booth SE, Gillmore JD et al. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 1998; 5: 262-265
    CrossrefPubMedGoogle Scholar
  • 7 Dember LM, Hawkins PN, Hazenberg BP et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007; 356: 2349-2360
    CrossrefPubMedGoogle Scholar
  • 8 Hazenberg BP, Bijzet J, Limburg PC et al. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid 2007; 14: 133-140
    CrossrefPubMedGoogle Scholar
  • 9 Immonen K, Finne P, Hakala M et al. No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases -- data from the Finnish national registry for kidney diseases. J Rheumatol 2008; 35: 1334-1338
    PubMedGoogle Scholar
  • 10 Koivuniemi R, Paimela L, Suomalainen R et al. Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 2008; 15: 262-268
    CrossrefPubMedGoogle Scholar
  • 11 Lachmann HJ, Goodman HJ, Gilbertson JA et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-2371
    CrossrefPubMedGoogle Scholar
  • 12 Linke RP, Oos R, Wiegel NM et al. Classification of amyloidosis: misdiagnosing by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem 2006; 108: 197-208
    CrossrefPubMedGoogle Scholar
  • 13 Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-596
    CrossrefPubMedGoogle Scholar
  • 14 Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011; 29: 1924-1933
    CrossrefPubMedGoogle Scholar
  • 15 Nakamura T, Higashi S, Tomoda K et al. Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Rheumatology 2012; 51: 2064-2069
    CrossrefPubMedGoogle Scholar
  • 16 Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly 2012; 142: w13580
    PubMedGoogle Scholar
  • 17 Okuda Y, Yamada T, Matsuura M et al. Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis. Amyloid 2011; 18: 108-111
    CrossrefPubMedGoogle Scholar
  • 18 Okuda Y, Ohnishi M, Matoba K et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol 2013; Mar 5. [Epub ahead of print].
    PubMedGoogle Scholar
  • 19 Schönland SO, Hegenbart U, Bochtler T et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 2012; 119: 488-493
    CrossrefPubMedGoogle Scholar
  • 20 Sipe JD, Benson MD, Buxbaum JN et al. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012; 19: 167-170
    CrossrefPubMedGoogle Scholar
  • 21 Sponarova J, Nyström SN, Westermark GT. AA-amyloidosis can be transferred by peripheral blood monocytes. PLoS One 2008; 3: e3308
    CrossrefPubMedGoogle Scholar
  • 22 Stankovic Stojanovic K, Delmas Y, Torres PU et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant 2012; 27: 1898-1901
    CrossrefPubMedGoogle Scholar
  • 23 Stix B, Kähne T, Sletten K et al. Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3. Am J Pathol 2001; 159: 561-570
    CrossrefPubMedGoogle Scholar
  • 24 Tishko AN, Lapin SV, Vavilova TV et al. Early diagnostics of kidney damage in longstanding rheumatoid arthritis and amyloidosis. Amyloid 2011; 18 S1: 217-218
    CrossrefPubMedGoogle Scholar
  • 25 Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265: 501-523
    CrossrefPubMedGoogle Scholar
  • 26 van Gameren II, Hazenberg BP, Bijzet J et al. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 2006; 54: 2015-2021
    CrossrefPubMedGoogle Scholar
  • 27 van der Hilst JC. Recent insights into the pathogenesis of type AA amyloidosis. Scientific World Journal 2011; 11: 641-650
    CrossrefPubMedGoogle Scholar
  • 28 Westermark P, Stenkvist B. A new method for the diagnosis of systemic amyloidosis. Arch Intern Med 1973; 132: 522-523
    CrossrefPubMedGoogle Scholar